Annual report pursuant to Section 13 and 15(d)

ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.22.2
ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended 36 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Sep. 15, 2022
Noncontrolling interests $ (141,708) $ (136,914)  
Cash equivalents 0 0  
Cash balances over insured amount 16,982,000    
Restricted Cash 87,506 46,726  
Asset impairment charges $ 0 $ 0  
Shares considered antidilutive 2,243,838 2,836,062  
Amortization of deferred financing costs $ 0 $ 0  
Contract revenue 294,165 659,104  
Revenue 294,165 659,104  
Research and development expenses 2,341,000 2,072,000  
Subaward With University Of Pittsburgh [Member]      
Revenue 64,467 34,233  
Phase 2 Melanoma Cancer Contract [Member]      
Government contract revenue 229,698 436,427  
Breast Cancer Grant [Member]      
Revenue   $ 188,444  
Melanoma Cancer Contract Phase 2 [Member]      
Award Contract amount     $ 1,860,561
Subaward With University Of Pittsburgh [Member]      
Award Contract amount $ 256,750    
E S I [Member]      
Equity ownership percentage 80.00% 80.00%  
Noncontrolling interests $ 141,708 $ 136,914